Business
Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”
Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named \"Best Pharmaceuticals Innovator of the Year - Europe\" by The European, a quarterly business publication published by CP Media Global Ltd in London.\"We are very honored to receive this award,\" said Massimo Radaelli, PhD, Chief Executive Officer of Napo Therapeutics and President of Jaguar International, \"as we continue to be laser-focused on our mission of expanding access to crofelemer in Europe for orphan and rare diseases.\"In participation with Jaguar and Jaguar family company Napo Pharmaceuticals, Napo Therapeutics is supporting investigator-initiated proof-of-concept (POC) studies of crofelemer for the rare disease indications of microvillus inclusion disease (MVID) and short bowel syndrome (SBS) with intestinal failure in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025. Additionally, a phase 2 trial of crofelemer in adult SBS patients with intestinal failure is expected to initiate before the end of 2024, as is a phase 2 trial of crofelemer in pediatric MVID patients. In accordance with the guidelines of specific EU countries, published data from clinical investigations in such rare diseases could support early patient access to crofelemer for these debilitating conditions in those countries.Some SBS patients are subject to intestinal failure, often requiring parenteral nutrition (PN) up to 7 days a week. Intestinal failure is associated with significant morbidity and mortality; and high medical expenses associated with PN. SBS patients with intestinal failure also have severe chronic diarrhea, and the associated sequelae from diarrhea, including significant dehydration, metabolic acidosis or alkalosis and malnutrition, and other secondary symptoms, and these symptoms emerge either early or late, and many times become life-threatening.MVID, an ultrarare congenital diarrheal disorder, is a severe infantile disease characterized by diarrhea, malabsorption, and acid/base instability, requiring intens...